Numinus Wellness Inc.

Equities

NUMI

CA67054W1032

Biotechnology & Medical Research

Delayed Toronto S.E. 01:22:54 2024-06-25 pm EDT 5-day change 1st Jan Change
0.045 CAD -10.00% Intraday chart for Numinus Wellness Inc. -10.00% -59.09%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Numinus Wellness Signs Letter of Intent to Buy MedBright AI Investments MT
Numinus Wellness Brief: MedBright AI Announcing Strategic Acquisition by Numinus Wellness MT
Numinus Wellness Inc. Appoints Jaime Gerber to Numinus Intelligence Board CI
Numinus Wellness Inc. executed a letter of intent to acquire MedBright AI Investments Inc. from Michael Dalsin and others for CAD 9.6 million. CI
Numinus Wellness Inc. Announces Its Cedar Clinical Research Select for Cybin's Phase 3 Pivotal Multinational Clinical Trial of CYB003 CI
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD CI
Transcript : Numinus Wellness Inc. - Shareholder/Analyst Call
Numinus Wellness Secures Health Canada Approval for Study Into Group Model For MDMA-Assisted Therapy MT
Numinus Wellness Brief: Says Received Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy MT
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy CI
Numinus Wellness to Focus on U.S. Operations as it Transitions Out of Canada MT
Numinus Wellness Brief: Announces a strategic plan designed to streamline expenses and "Sharpen" focus on Higher-growth U.S. operations MT
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Cybin Selects Numinus Wellness Inc.'s Cedar Clinical Research as clinical research site for Its Phase 3 Study of CYB003 CI
Transcript : Numinus Wellness Inc., Q2 2024 Earnings Call, Apr 15, 2024
Numinus Wellness Drops 25% as it Explores Options for its Canadian Operations; FQ2 Profit Falls MT
Toronto Stocks Edge Lower; Parkland Shares Up After Rebuffing Call for Strategic Review DJ
Numinus Wellness Exploring Options For Canadian Operations; Comes After It Posted QoQ Decrease in Q2 Revenue, Gross Profit MT
Numinus Wellness Brief: Co Has decided to Explore Opportunities to "Redefine, divest and/or discontinue" its Canadian clinical operations MT
Numinus Wellness Brief: Says To Focus on U.S. operations and Citing "Strategic Adjustments" in its Canadian Market Presence MT
Numinus Wellness Posts QoQ Decrease in Q2 Revenue, Gross Profit MT
An undisclosed buyer agreed to acquire Canadian clinical operations from Numinus Wellness Inc.. CI
Numinus Wellness Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
PharmAla Biotech Signs Sale Agreement with Numinus Wellness MT
Numinus Wellness Submits Clinical Trial Application to Health Canada MT
Chart Numinus Wellness Inc.
More charts
Numinus Wellness Inc. is a Canada-based mental health care company. The Company helps people to heal and be well through the development and delivery of mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Company's segments include Clinical Research Operations, Canadian Clinic Network and US Clinic Network. Its Clinical Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Its Canadian Clinic Network segment includes wellness clinics based in Canada offering clinical services, including traditional therapy and counseling, ketamine-assisted therapies, mindfulness programs, and virtual psychotherapy. The US Clinic Network segment includes wellness clinics based in the United States that offers clinical services, such as psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.05
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. NUMI Stock
  4. News Numinus Wellness Inc.
  5. Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003